

14 August 2025

ASX Announcement

DATE OF ANNUAL GENERAL MEETING AND CLOSING DATE FOR DIRECTOR NOMINATIONS

MELBOURNE Australia, 14 August 2025: Australian antiviral drug development company, Island Pharmaceuticals Ltd (**ASX: ILA; Island or the Company**) advises, in accordance with ASX Listing Rule 3.13.1, that its Annual General Meeting will be held on Thursday, 9 October 2025.

An item of business at the AGM will be the re-election of Directors. In accordance with clause 13.3 of the Company's Constitution, the closing date for the receipt of nominations from persons wishing to be considered for election as a director is Thursday, 21 August 2025.

Any nominations must be received by the Company in writing by no later than 5:00 pm (Melbourne time) on Thursday, 21 August 2025.

– Ends –

The release of this announcement was authorised by CEO and Managing Director, David Foster.

For further information, please contact:

David Foster
Managing Director
Island Pharmaceuticals Ltd
info@islandpharmaceuticals.com

Investors and media, for further information, please contact:

Henry Jordan
Six Degrees Investor Relations
+61 (0) 431 271 538
henry.jordan@sdir.com.au



About Island Pharmaceuticals

Island (ASX: ILA) is a drug repurposing company, focused on areas of unmet need for antiviral therapeutics to address infectious diseases. Our lead asset is ISLA-101, a drug with a well- established safety profile, being repurposed for the prevention and treatment of dengue2 fever and other mosquito (or vector) borne diseases.

If ISLA-101 achieves FDA approval, and certain other criteria are met, Island may be eligible to obtain a "Priority Review Voucher" at the time of FDA approval. This means that as well as getting approval to manufacture and sell ISLA-101, the Priority Review Voucher (PRV) could permit Island to expedite the FDA approval process for a new drug or sell the PRV in a secondary market.

Island encourages all current investors to go paperless by registering their details with the Company's share registry, Automic Registry Services, whose contact info is housed on the Shareholder Services page of the Company's website

Visit www.islandpharmaceuticals.com for more on Island.